NeuVax/Herceptin Combo Promotes Disease-free Survival in TNBC

NeuVax/Herceptin Combo Promotes Disease-free Survival in TNBC
Long-term treatment with a combination of NeuVax (nelipepimut-S) and Herceptin (trastuzumab) is safe and extends the time without disease resurgence in women with triple-negative breast cancer, according to final results of a Phase 2b trial. NeuVax, developed by Sellas Life Sciences, is an investigational cancer vaccine that contains small pieces derived from human epidermal growth factor receptor 2 (HER2), a protein found in many breast cancer cells. Once injected into the patient, NeuVax “teaches” the immune system to recognize and mount a response against HER2, ultimately killing cancer cells. The randomized, controlled Phase 2b study (NCT01570036) assessed the efficacy and safety of the treatment combination in patients with low levels of HER2, including people with triple-negative breast cancer (TNBC), which refers to the lack of HER2, estrogen receptors, and progesterone receptors. All participants were disease-free after standard therapy. A total of 275 patients were included; 136 received both NeuVax and Genentech’s Herceptin and 139 received Herceptin alone. NeuVax was given intradermally (within the skin) every three weeks for a total of six vaccinations. Herceptin was administered every three weeks for one year. All patients were also given 
Subscribe or to access all post and page content.